| تعداد نشریات | 286 |
| تعداد نشریات سازمان | 84 |
| تعداد شماره‌ها | 2,829 |
| تعداد مقالات | 32,098 |
| تعداد مشاهده مقاله | 40,864,080 |
| تعداد دریافت فایل اصل مقاله | 18,113,700 |
A Review on Rubella Vaccine: Iran (1975-2019) | ||
| Archives of Razi Institute | ||
| مقاله 2، دوره 76، شماره 2، شهریور 2021، صفحه 167-192 اصل مقاله (951.15 K) | ||
| نوع مقاله: Review Article | ||
| شناسه دیجیتال (DOI): 10.22092/ari.2021.353242.1594 | ||
| نویسندگان | ||
| A Shafayi؛ A Mohammadi* | ||
| Human Viral Vaccines Department, Razi Vaccine and Serum Research Institute (RVSRI), Hessark Karadj, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran | ||
| چکیده | ||
| The first Attenuated rubella vaccine was developed by Parkman and Meyer in 1966. Ten years later in the 1975s, the rubella vaccine was developed in Razi Vaccine and serum research institute) RVSRI). In 1977, the rubella TAKAHASHI vaccine successfully passed the clinical trial and was initially used voluntarily only in the private sector. Since 1987, the administration of rubella as MMR (Measles/AIK-C; Rubella/TAKAHASHI; Mumps/HOSHINO) strain vaccine has been included in the immunization program in Iran. This review article focused on the development and production of the rubella TAKAHASHI/HDC vaccine in RVSRI. The herd immunity and rubella cases were investigated in the pre- and post-vaccine era. The effectiveness and proper coverage of the rubella vaccine led to the elimination of rubella from Iran in 2019. The current study aimed to assess local rubella vaccine manufacturing and its consequences on rubella elimination from Iran, using various search engines. A complete search was carried out in medical databases, including PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, Magiran, and Google Scholar. Within 1972-1975, Rubella TAKAHASHI/HDC vaccine was developed by RVSRI and successfully passed clinical trial in 1977. Over the four last decades (1980-2020), more than 40 million infants, young, and adults were vaccinated by million doses of local Rubella, measles-rubella (MR) or measles-mumps-rubella (MMR) vaccine in Iran. In 1972, the pre-vaccine era, the overall sensitivity to rubella infection was 69% in one-year-old Iranian children and 23% in childbearing women. The use of a safe, inexpensive, and effective vaccine increased herd immunity to 95% (85%-99%) in our country. During the last two decades, we have witnessed a 91% decline in the confirmed rubella cases, from 1124 in 2000 to 33 cases in 2018. The current article presented the process of vaccine development, tracked it through more than four decades, and discussed disease status before and after the rubella vaccine era, as well as the history of its elimination from Iran. The effectiveness of the local Razi Rubella vaccine resulted in a significant increase in seroprevalence in Iran. Expanded vaccination against rubella, usually with measles, has led to the elimination of Rubella from Iran as confirmed by World Health Organization in 2019. | ||
| کلیدواژه‌ها | ||
| Iran؛ Razi؛ Vaccine؛ Rubella؛ TAKAHASHI؛ Production؛ Congenital Rubella Syndrome؛ Elimination | ||
| عنوان مقاله [English] | ||
| مروری بر واکسن سرخجه :ایران(1975-2019) | ||
| چکیده [English] | ||
| اولین واکسن سرخچه ضعیف شده جهان درسال 1966 توسط Parkman و Meyer ساخته شد. ده سال بعد در سال 1975 واکسن سرخچه سویه تاکاهاشی بااستفاده از سلول دیپلوئید ریه جنین انسان در موسسه تحقیقات واکسن و سرم رازی (RVSRI) تولید شد. در سال 1977 آزمایش بالینی واکسن سرخچه تاکاهاشی با موفقیت انجام شد. در ابتدا ، این واکسن به صورت مونوالان فقط توسط بخش خصوصی به صورت اختیاری و داوطلبانه استفاده می شد. از سال 1987 ، واکسن فوق به صورت سه گانه MMR (Measles / AIK-C؛ Rubella / Takahashi؛ Mumps / HOSHINO) برای برنامه ایمن سازی در ایران گنجانده شد. این مقاله مروری ، روی فرآیند تولید واکسن سرخجه Takahashi / HDC در RVSRI متمرکزشده است. ایمنی جمعی و موارد سرخچه در دوران قبل و بعد از واکسن نیز بررسی شده است. اثر بخشی و پوشش مناسب واکسن فوق باعث از حذف سرخچه در سال 2019 از ایران شد. | ||
| کلیدواژه‌ها [English] | ||
| سرخجه :تاکاهاشی: تولید: حذف بیماری:رازی | ||
|
سایر فایل های مرتبط با مقاله
|
||
| مراجع | ||
|
Blac Abernathy, E.S., Hubschen, J.M., Muller, C.P., Jin, L., Brown, D., Komase, K., et al., 2011. Status of global virologic surveillance for rubella viruses. J Infect Dis 204 1, 524-532.
Amini, B., 1996. A study of relationship between antibody of Rubella antivirus and number of pregnancy. J Zanjan Univ Med Sci 170, 11-19.
Azami, M., Jaafari, Z., Soleymani, A., Badfar, G.H., Abbasalizadeh, S.H., 2019. Rubella Immunity in Pregnant Iranian Women: A Systematic Review and Meta-Analysis. Int J Fertil Steril 13, 169-177.
Banatvala, J., Peckham, C., 2007. Rubella Viruses (2007),
Elsevier.
Beck, E.S., 1969. Review of studies with inactivated rubella virus. Am J Dis Child 118, 328-333.
Bordbar, N., Habibi, G., Shafiei, A., 2010. Sequence and Phylogenetic Analysis of Wild Type Rubella virus isolated in Iran. Iran J Virol. 4, 28-37.
Buynak, E.B., Hilleman, M.R., Weibel, R.E., Stokes, J., Jr., 1968. Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing. JAMA 204, 195-200.
Cutts, F.T., Robertson, S.E., Diaz-Ortega, J.L., Samuel, R., 1997. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 2: vaccination against rubella. Bull World Health Organ, 75, 69-80.
Cutts, F.T., Vynnycky, E., 1999. Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol 28, 1176-1184.
Esteghamati, A., Gouya, M.M., Zahraei, S.M., Dadras, M.N., Rashidi, A., Mahoney, F., 2007. Progress in measles and rubella elimination in Iran. Pediatr Infect Dis J 26, 1137-1141.
Rahimi, F., Sarafnegad, A., Salarbehzadi, S., 1994. Survey of rubella immunity in Tehran. Azad University.
Farhoud, D., Siddiqui, H., Solati, A.S., Alinejad, Z., Mohammad Ibrahim, S., 1996. Prevalence of rubella in women of premarital or reproductive age. Iran J Health 24, 1-6.
Ghafourian Boroujerdinia, M., Mohammad Jaffari, R., Khodadady, A., 2003. Seroepidemiology of Rubella amog Pregnant Women in Ahwaz, Iran. Jundishapur Sci Med J 38.
Ghafourian Boroujerdinia, M., Pakzad, P., 1996. Evaluation of rubella in pregnant women and children with and congenital rubella in Khuzestan province. Med Sci J Ahwaz Uni Med Sci 19.
Hilleman, M.R., Buynak, E.B., Whitman, J.E., Jr., Weibel, R.W., Stokes, J., Jr., 1969. Live attenuated rubella virus vaccines. Experiences with duck embryo cell preparations. Am J Dis Child 118, 166-171.
Hobman, T., Chantler, J., 2007. Rubella virus. In: Knipe, D.M., Howley, P.M. (Eds.), Fields' Virology Text book, pp. 1069-1101.
Huygelen, C., Peetermans, J., Prinzie, A., 1969. An attenuated rubella virus vaccine (Cendehill 51 strain) grown in primary rabbit kidney cells. Prog Med Virol 11, 107-125.
Jafari, E., Mohammadi, A., Arabzadeh, S., Esna-Ashari, F.,
Sadigh, Z., Shokri, G., et al., 2012. Evaluation of Cell Mediated Immunity following Rubella Vaccination Using Lymphocyte Proliferation. Iran J Virol 6, 20-26.
Kabiri, M., Moattari, A., 1993. The rubella immunosurveillance of Iranian females: an indication of the emergence of rubella outbreak in Shiraz, Iran. Iran J Med Sci 18, 134-137. Kirby, T., 2015. Rubella is eliminated from the Americas. Lancet Infect Dis 15, 768-769.
Kono, R., Hibi, M., Hayakawa, Y., Ishii, K., 1969. Experimental Vertical Transmission of Rubella Virus in Rabbits. The Lancet 293, 343-347.
Mahmoudi, M., Vahedi, E., 2007. Comparison of Immunity against Rubella before and after Measles–Rubella Vaccination in 15-23 year-old Women. Med J Mashhad Uni of Med Sci 50, 177-184.
Metcalf, C.J., Lessler, J., Klepac, P., Cutts, F., Grenfell, B.T., 2012. Impact of birth rate, seasonality and transmission rate on minimum levels of coverage needed for rubella vaccination. Epidemiol Infect 140, 2290-2301.
Meyer, H.M., Jr., Parkman, P.D., Panos, T.C., 1966. Attenuated rubella virus. II. Production of an experimental live-virus vaccine and clinical trial. N Engl J Med 275, 575-580.
Mirchamsy, H., 1996. Rubella virus. In: Mirchamsy, H. (Ed.), General Information about prevention and treatment with vaccine and serum, University of Tehran Press, pp. 241-213.
Mirchamsy, H., Shafyi, A., Bahrami, S., Kamali, M., Nazari, P., 1976. Use of human diploid cell MRC-5, for production of measles and rubella virus vaccines. Dev Biol Stand 37, 297-300.
Modarres, S., Oskoii, N.N., 1996. The immunity of children and adult females to rubella virus infection in Tehran. Iran J Med Sci 21, 69-73.
Naficy, K., Nategh, R., Ahangary, S., Mohsenin, H., 1970. Artificial challenge studies in rubella. Utilization of RA 27-3 rubella vaccines, rubella naturally acquired seropositives, and rubella susceptible children. Am J Dis Child 120, 520-523.
Naficy, K., Saidi, S., 1970. Serological survey on viral antibodies in Iran. Trop Geogr Med 22, 183-188.
Naficy, K., Saidi, S., Nategh, R., Mostatab, A., Akbarshahy, E., 1967. Comparative study of live attenuated and further attenuated measles vaccines in rural areas of Iran. Arch Gesamte Virusforsch 22, 11-22.
Nategh, R., Ebrahimpour, 1985. Evaluation of rubella immunity in women aged 18-15 years in East Azerbaijan. Med J Uni Tabriz 1, 26-27. Owada, Y., Yamane, Y., Nagashima, T., Adachi, A., Ikumi, H., 1973. Studies on the live attenuated rubella virus vaccine. II. Research concerning attenuation of "Takahashi
strain" isolated in Japan. Kitasato Arch Exp Med 46, 93-103.
Pakzad, P., Ghafourian, M., 1996. Rubella survey among pregnant women and congenitally infected infants in Khuzestan province. Med J Ahwaz 19, 56-66.
Pakzad, P., Moattari, A., 1987. Serological study of the immunity to Rubella infection among the adult girls, pregnant and non-pregnant women, resident in Ahwaz. Jundishapur Sci Med J 5, 52-60.
Parkman, P.D., Buescher, E.L., Artenstein, M.S., 1962. Recovery of rubella virus from army recruits. Proc Soc Exp Biol Med 111, 225-230.
Peetermans, J., Huygelen, C., 1967. Attenuation ob rubella virus by serial passage in primary rabbit kidney cell cultures. I. Growth characteristics in vitro and production of experimental vaccines at different passage levels. Arch Gesamte Virusforsch 21, 133-143.
Plotkin, S.A., Farquhar, J., Katz, M., Ingalls, T.H., 1967. A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion. Am J Epidemiol 86, 468-477.
Plotkin, S.A., Farquhar, J.D., Katz, M., Buser, F., 1969. Attenuation of RA 27-3 rubella virus in WI-38 human diploid cells. Am J Dis Child 118, 178-185.
Plotkin, S.A., Orenstein, W.A., 2012. Rubella vaccine, Vaccines, Philadelphia WB Saunders.
Polk, B.F., Modlin, J.F., White, J.A., DeGirolami, P.C., 1982. A controlled comparison of joint reactions among women receiving one of two rubella vaccines. Am J Epidemiol 115, 19-25.
Rivailler, P., Abernathy, E., Icenogle, J., 2017. Genetic diversity of currently circulating rubella viruses: a need to define more precise viral groups. J Gen Virol 98, 396-404.
Sabin, A.P.S.A., 1969. Discussion on session V., the International Conference on Rubella Immunization. Amer J Dis Child pp. 378-380.
Sadigh, Z.A., Shafyi, A., Akhavizadegan, M.A., Sabiry, G.M., Sassani, A., 1998. Evaluation of immunogenicity in MMR vaccine prepared with (AIK-C, S#12, and TAKAHASHI) strains in adult volunteers. RAZI Institute.
Sadighi, J., Eftekhar, H., Mohammad, K., 2005. Congenital rubella syndrome in Iran. BMC Infect Dis 5, 44.
Saidi, S., 1972. Epidemiological survey of rubella immunity
in Iran. Bull World Health Organ 46,563-565.
Sever, J.L., Schiff, G.M., Huebner, R.J., 1963. Inactivated rubella virus vaccine. J Lab Clin Med.
Shafyi, A., Mirchamsy, H., Yousefi, I., 1996. Immunology and vaccine failure in measles vaccination. Res Reconstruct Sci Educat Quarter Agricult Minist 31, 108-117.
Shafyi, A., Mohammadi, A., 2018. Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017). Jundishapur J Microbiol 11, e60725.
Shafyi, A., Shafiee, M., Mirchamsy, H., Mohammadi, A., Keshawarz, M., Taqavian, M., et al., 2005. Isolation of Rubella Virus from Patients with Progressive Rubella Pan-Encephalitis. Arch Razi Inst 59, 25-33.
Shishido, A., Ohtawara, M., 1976. Development of attenuated rubella virus vaccines in Japan. Jpn J Med Sci Biol 29, 227-253.
Veale, H., 1866. History of an Epidemic of Rötheln, with Observations on Its Pathology. Edinb Med J 12, 404-414.
WHO, 1991. Rubella and congenital rubella syndrome in developing countries. 14th meeting.
WHO, 2005. Rubella, Congenital rubella syndrome: Where are we? Division of Communicable Disease Control Newsletter.
WHO, 2009. Measles & Rubella Surveillance. Field Manual for Communicable Diseases Surveillance Staff WHO-MOH IRAQ.
WHO, 2018. Assessment report of the Global Vaccine Action Plan. World Health organization, Geneva.
Zahraei, S.M., Mokhtari-Azad, T., Sabouri, A., Khazaei, S., Karami, M., 2019. Sero-epidemiological evaluation of rubella immunity among pre-marriage women in Iran. Hum Vaccin Immunother 15, 2117-2120. | ||
|
آمار تعداد مشاهده مقاله: 2,871 تعداد دریافت فایل اصل مقاله: 980 |
||
